KP.2, a JN.1 sub-lineage with #FLiRT combo mutations features 16 times in the @US_FDA brief. #VRBPAC should consider recommending KP.2 as the monovalent antigen of choice for #COVID19 vaccine manufacturing (then #ACIP @CDCgov should follow suit) www.fda.gov/media/179003/download pic.twitter.com/bY5mHbvy2T

#COVID19 #VariantDashboard - #USA | 06/03/24 #SARSCoV2 #Lineages #30DAYTRENDS KP.2 (9.1%) LB.1 (8.7%)👀 JN.1.7 (5.7%) JN.1.16.1 (5.4%) KP.3 (4.8%) JN.1.16 (4.5%) KP.1.1 (4.3%) KP.2.3 (4.3%) JN.1.4 (3.4%) JN.1 (3.2%) KP.3.1 (2.9%) tinyurl.com/mryj4uu7 1/n

Well, that's promising. Although now we also need to consider FLuQE mutations in addition to FLiRT (and yes, they use the informal FLiRT nickname, because it is useful -- officially it's either "Omicron" or technical PANGO names). From the FDA: www.fda.gov/media/179003/download pic.twitter.com/klOneKaezN

NY Times: "As new variants of the coronavirus continue to gain traction, doctors and researchers are bracing for a potential rise in cases this summer. KP.2, one of these variants, now accounts for 28.5 percent of cases."👇 www.nytimes.com/2024/06/03/well/live/covid-symptoms-treatment-flirt-variants.html